Search research articles
Contact Us
Filters
Showing results (71-80 of 132) with videos related to
Page
of 14
Sort By:
Blood
|
June 15, 1992
In vitro culture of common acute lymphoblastic leukemia blasts: effects of interleukin-3, interleukin-7, and accessory cells
M Eder, O G Ottmann, T E Hansen-Hagge, et al.
Blood
|
October 27, 1998
High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-free conditions
A J Schilz, G Brouns, H Knöss, et al.
Leukemia
|
June 22, 2001
TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS
S Koschmieder, W K Hofmann, J Kunert, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex
E Puccetti, B Sennewald, F Fosca-Ferrara, et al.
Leukemia
|
March 1, 1994
Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes
A Ganser, G Seipelt, W Verbeek, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
January 1, 1991
Recombinant human interleukin-3 in patients with hematopoietic failure
A Ganser, A Lindemann, G Seipelt, et al.
Blood
|
August 15, 1990
Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure
A Ganser, A Lindemann, G Seipelt, et al.
Leukemia
|
September 13, 2003
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment
U J Scheuring, H Pfeifer, B Wassmann, et al.
American Journal of Clinical Oncology
|
January 1, 1991
Clinical effects of recombinant human interleukin-3
A Ganser, A Lindemann, G Seipelt, et al.
Blood
|
May 15, 1992
Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study
A Ganser, A Lindemann, O G Ottmann, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 132) with videos related to
Sort By:
Page
of 14
Blood
|
June 15, 1992
In vitro culture of common acute lymphoblastic leukemia blasts: effects of interleukin-3, interleukin-7, and accessory cells
M Eder, O G Ottmann, T E Hansen-Hagge, et al.
Blood
|
October 27, 1998
High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-free conditions
A J Schilz, G Brouns, H Knöss, et al.
Leukemia
|
June 22, 2001
TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS
S Koschmieder, W K Hofmann, J Kunert, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex
E Puccetti, B Sennewald, F Fosca-Ferrara, et al.
Leukemia
|
March 1, 1994
Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes
A Ganser, G Seipelt, W Verbeek, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
January 1, 1991
Recombinant human interleukin-3 in patients with hematopoietic failure
A Ganser, A Lindemann, G Seipelt, et al.
Blood
|
August 15, 1990
Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure
A Ganser, A Lindemann, G Seipelt, et al.
Leukemia
|
September 13, 2003
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment
U J Scheuring, H Pfeifer, B Wassmann, et al.
American Journal of Clinical Oncology
|
January 1, 1991
Clinical effects of recombinant human interleukin-3
A Ganser, A Lindemann, G Seipelt, et al.
Blood
|
May 15, 1992
Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study
A Ganser, A Lindemann, O G Ottmann, et al.
Page
of 14